SSZ is a multi-target inhibitor, which targets multiple pathological mechanisms of Alzheimers disease (AD). SSZ targets acetylcholinesterase, butyrylcholinesterase, beta-site amyloid precursor protein cleavage enzyme 1 (BACE1), and gamma-secretase. SSZ ameliorates Alzheimers diseases and exhibits neuroprotective effect in mice[1].
